| Literature DB >> 29695457 |
Alphonsus H C Ng1,2, Ryan Fobel1,2, Christian Fobel1,2, Julian Lamanna1,2, Darius G Rackus1,2, Aimee Summers3, Christopher Dixon1, Michael D M Dryden1, Charis Lam1, Man Ho1,2, Nooman S Mufti2,4, Victor Lee2, Mohd Afiq Mohd Asri2, Edward A Sykes1,2, M Dean Chamberlain1,2, Rachael Joseph5, Maurice Ope5, Heather M Scobie6, Alaine Knipes3, Paul A Rota7, Nina Marano8, Paul M Chege9, Mary Njuguna9, Rosemary Nzunza9, Ngina Kisangau9, John Kiogora10, Michael Karuingi10, John Wagacha Burton11, Peter Borus12, Eugene Lam3, Aaron R Wheeler13,2,4.
Abstract
Serosurveys are useful for assessing population susceptibility to vaccine-preventable disease outbreaks. Although at-risk populations in remote areas could benefit from this type of information, they face several logistical barriers to implementation, such as lack of access to centralized laboratories, cold storage, and transport of samples. We describe a potential solution: a compact and portable, field-deployable, point-of-care system relying on digital microfluidics that can rapidly test a small volume of capillary blood for disease-specific antibodies. This system uses inexpensive, inkjet-printed digital microfluidic cartridges together with an integrated instrument to perform enzyme-linked immunosorbent assays (ELISAs). We performed a field validation of the system's analytical performance at Kakuma refugee camp, a remote setting in northwestern Kenya, where we tested children aged 9 to 59 months and caregivers for measles and rubella immunoglobulin G (IgG). The IgG assays were determined to have sensitivities of 86% [95% confidence interval (CI), 79 to 91% (measles)] and 81% [95% CI, 73 to 88% (rubella)] and specificities of 80% [95% CI, 49 to 94% (measles)] and 91% [95% CI, 76 to 97% (rubella)] (measles, n = 140; rubella, n = 135) compared with reference tests (measles IgG and rubella IgG ELISAs from Siemens Enzygnost) conducted in a centralized laboratory. These results demonstrate a potential role for this point-of-care system in global serological surveillance, particularly in remote areas with limited access to centralized laboratories.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29695457 DOI: 10.1126/scitranslmed.aar6076
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956